NSG 5240 ADVANCED PHARMACOLOGY
MIDTERM PRACTICE EXAM QUESTIONS AND
CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026/2027 Q&A | INSTANT
DOWNLOAD PDF| SOUTH COLLEGE
SECTION 1: FOUNDATIONAL CONCEPTS & REGULATORY ISSUES (Questions 1-20)
1. The U.S. Food and Drug Administration (FDA) regulates which of the following?
A. Prescribing practices of nurse practitioners
B. The official labeling for all prescription and over-the-counter drugs
C. State-level licensing requirements
D. Controlled substance scheduling
Correct Answer: B
Rationale: The FDA is responsible for ensuring the safety, efficacy, and security of drugs,
biological products, and medical devices. This includes approving and regulating the
official labeling for all prescription and OTC medications. Prescribing practices are
regulated by state boards, and controlled substance scheduling is overseen by the DEA .
2. Nurse practitioner prescriptive authority is ultimately regulated by:
A. The National Council of State Boards of Nursing (NCSBN)
B. The State Board of Nursing for each state
C. The U.S. Drug Enforcement Administration (DEA)
D. The State Board of Pharmacy
Correct Answer: B
Rationale: While the DEA regulates controlled substances at the federal level, the scope
of practice, including prescriptive authority for nurse practitioners, is determined and
regulated by the individual State Boards of Nursing .
3. Who oversees the APRN's prescribing of controlled substances?
A. The pharmaceutical board of the state
B. The federal government (DEA)
,C. The practice protocols of the hospital
D. State practice agreements only
Correct Answer: B
Rationale: The Drug Enforcement Administration (DEA) is the federal agency
responsible for regulating the prescribing and dispensing of controlled substances.
APRNs must register with the DEA to prescribe these medications .
4. Medication agreements or "Pain Medication Contracts" are recommended to be
used:
A. Universally for all prescribing for chronic pain
B. Only for patients with repeated requests for pain medication
C. Only when you suspect a patient is exhibiting drug-seeking behavior
D. Exclusively for patients with pain associated with malignancy
Correct Answer: A
Rationale: To ensure clarity, mutual understanding, and adherence to treatment plans,
and to mitigate the risk of misuse, medication agreements are recommended for all
patients receiving chronic pain therapy, regardless of the perceived risk .
5. Which of the following information is NOT required on a standard prescription
for a non-controlled medication?
A. Prescriber's name and signature
B. Patient's name and address
C. Prescriber's DEA number
D. Date of prescribing
Correct Answer: C
Rationale: A DEA number is only required for prescriptions of controlled substances.
Standard prescriptions for non-controlled medications require the date, patient
information, prescriber information, drug name/strength, quantity, and directions for
use .
6. Which statement best describes a "black box warning"?
A. A warning that all drugs carry regarding safe handling
B. The strictest warning required by the FDA, indicating serious or life-threatening risks
C. A standard warning found on all over-the-counter medications
D. An advisory from the DEA regarding potential for abuse
,Correct Answer: B
Rationale: A black box warning (or boxed warning) is the most serious warning required
by the FDA, appearing on the labeling of prescription drugs that carry significant risks of
serious or life-threatening adverse effects .
7. "Off-label" use of a medication means:
A. Using a medication that is not approved by the FDA
B. Using an FDA-approved medication for a purpose, in a population, or at a dosage not
specified in the approved labeling
C. Using a medication past its expiration date
D. Prescribing a controlled substance without a DEA number
Correct Answer: B
Rationale: Off-label use is common and legal in many areas of medicine. It is based on
evidence and clinical experience, but the manufacturer cannot promote the drug for
these unapproved uses .
8. The FDA's pregnancy labeling categories (A, B, C, D, X) have been replaced by
the "Pregnancy and Lactation Labeling Rule" (PLLR), which requires:
A. A single standardized risk statement for all drugs
B. Narrative summaries of risk, clinical considerations, and a data section
C. A letter category based on animal and human studies
D. A mandatory registry for all exposed pregnancies
Correct Answer: B
Rationale: The PLLR, implemented in 2015, replaced the letter categories. It requires
drug labeling to include detailed narrative sections on "Pregnancy," "Lactation," and
"Females and Males of Reproductive Potential," providing more meaningful information
for clinical decision-making .
9. A patient's genetic profile can influence drug metabolism, a field of study
known as:
A. Pharmacodynamics
B. Pharmacoepidemiology
C. Pharmacogenomics
D. Toxicology
, Correct Answer: C
Rationale: Pharmacogenomics (or pharmacogenetics) is the study of how an individual's
genetic makeup affects their response to drugs. This can influence drug efficacy,
metabolism, and the risk of adverse effects .
10. Which federal agency classifies potentially abused substances into schedules (I-
V)?
A. FDA
B. DEA
C. NIH
D. CDC
Correct Answer: B
Rationale: The Drug Enforcement Administration (DEA) is responsible for enforcing the
controlled substances laws and regulations and for classifying drugs into schedules
based on their medical use and potential for abuse .
11. A Schedule II controlled substance has:
A. No accepted medical use and high abuse potential
B. Accepted medical use and high abuse potential with severe psychological or physical
dependence
C. Accepted medical use and low abuse potential
D. Accepted medical use and limited dependence potential
Correct Answer: B
Rationale: Schedule II drugs have a high potential for abuse and may lead to severe
psychological or physical dependence. They have accepted medical uses (unlike
Schedule I) .
12. A Schedule IV controlled substance has:
A. High abuse potential and no medical use
B. Low abuse potential and accepted medical use
C. Moderate abuse potential and accepted medical use
D. High abuse potential and accepted medical use
Correct Answer: C
Rationale: Schedule IV substances have a lower potential for abuse relative to Schedule
III. Examples include benzodiazepines, zolpidem, and tramadol .
MIDTERM PRACTICE EXAM QUESTIONS AND
CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026/2027 Q&A | INSTANT
DOWNLOAD PDF| SOUTH COLLEGE
SECTION 1: FOUNDATIONAL CONCEPTS & REGULATORY ISSUES (Questions 1-20)
1. The U.S. Food and Drug Administration (FDA) regulates which of the following?
A. Prescribing practices of nurse practitioners
B. The official labeling for all prescription and over-the-counter drugs
C. State-level licensing requirements
D. Controlled substance scheduling
Correct Answer: B
Rationale: The FDA is responsible for ensuring the safety, efficacy, and security of drugs,
biological products, and medical devices. This includes approving and regulating the
official labeling for all prescription and OTC medications. Prescribing practices are
regulated by state boards, and controlled substance scheduling is overseen by the DEA .
2. Nurse practitioner prescriptive authority is ultimately regulated by:
A. The National Council of State Boards of Nursing (NCSBN)
B. The State Board of Nursing for each state
C. The U.S. Drug Enforcement Administration (DEA)
D. The State Board of Pharmacy
Correct Answer: B
Rationale: While the DEA regulates controlled substances at the federal level, the scope
of practice, including prescriptive authority for nurse practitioners, is determined and
regulated by the individual State Boards of Nursing .
3. Who oversees the APRN's prescribing of controlled substances?
A. The pharmaceutical board of the state
B. The federal government (DEA)
,C. The practice protocols of the hospital
D. State practice agreements only
Correct Answer: B
Rationale: The Drug Enforcement Administration (DEA) is the federal agency
responsible for regulating the prescribing and dispensing of controlled substances.
APRNs must register with the DEA to prescribe these medications .
4. Medication agreements or "Pain Medication Contracts" are recommended to be
used:
A. Universally for all prescribing for chronic pain
B. Only for patients with repeated requests for pain medication
C. Only when you suspect a patient is exhibiting drug-seeking behavior
D. Exclusively for patients with pain associated with malignancy
Correct Answer: A
Rationale: To ensure clarity, mutual understanding, and adherence to treatment plans,
and to mitigate the risk of misuse, medication agreements are recommended for all
patients receiving chronic pain therapy, regardless of the perceived risk .
5. Which of the following information is NOT required on a standard prescription
for a non-controlled medication?
A. Prescriber's name and signature
B. Patient's name and address
C. Prescriber's DEA number
D. Date of prescribing
Correct Answer: C
Rationale: A DEA number is only required for prescriptions of controlled substances.
Standard prescriptions for non-controlled medications require the date, patient
information, prescriber information, drug name/strength, quantity, and directions for
use .
6. Which statement best describes a "black box warning"?
A. A warning that all drugs carry regarding safe handling
B. The strictest warning required by the FDA, indicating serious or life-threatening risks
C. A standard warning found on all over-the-counter medications
D. An advisory from the DEA regarding potential for abuse
,Correct Answer: B
Rationale: A black box warning (or boxed warning) is the most serious warning required
by the FDA, appearing on the labeling of prescription drugs that carry significant risks of
serious or life-threatening adverse effects .
7. "Off-label" use of a medication means:
A. Using a medication that is not approved by the FDA
B. Using an FDA-approved medication for a purpose, in a population, or at a dosage not
specified in the approved labeling
C. Using a medication past its expiration date
D. Prescribing a controlled substance without a DEA number
Correct Answer: B
Rationale: Off-label use is common and legal in many areas of medicine. It is based on
evidence and clinical experience, but the manufacturer cannot promote the drug for
these unapproved uses .
8. The FDA's pregnancy labeling categories (A, B, C, D, X) have been replaced by
the "Pregnancy and Lactation Labeling Rule" (PLLR), which requires:
A. A single standardized risk statement for all drugs
B. Narrative summaries of risk, clinical considerations, and a data section
C. A letter category based on animal and human studies
D. A mandatory registry for all exposed pregnancies
Correct Answer: B
Rationale: The PLLR, implemented in 2015, replaced the letter categories. It requires
drug labeling to include detailed narrative sections on "Pregnancy," "Lactation," and
"Females and Males of Reproductive Potential," providing more meaningful information
for clinical decision-making .
9. A patient's genetic profile can influence drug metabolism, a field of study
known as:
A. Pharmacodynamics
B. Pharmacoepidemiology
C. Pharmacogenomics
D. Toxicology
, Correct Answer: C
Rationale: Pharmacogenomics (or pharmacogenetics) is the study of how an individual's
genetic makeup affects their response to drugs. This can influence drug efficacy,
metabolism, and the risk of adverse effects .
10. Which federal agency classifies potentially abused substances into schedules (I-
V)?
A. FDA
B. DEA
C. NIH
D. CDC
Correct Answer: B
Rationale: The Drug Enforcement Administration (DEA) is responsible for enforcing the
controlled substances laws and regulations and for classifying drugs into schedules
based on their medical use and potential for abuse .
11. A Schedule II controlled substance has:
A. No accepted medical use and high abuse potential
B. Accepted medical use and high abuse potential with severe psychological or physical
dependence
C. Accepted medical use and low abuse potential
D. Accepted medical use and limited dependence potential
Correct Answer: B
Rationale: Schedule II drugs have a high potential for abuse and may lead to severe
psychological or physical dependence. They have accepted medical uses (unlike
Schedule I) .
12. A Schedule IV controlled substance has:
A. High abuse potential and no medical use
B. Low abuse potential and accepted medical use
C. Moderate abuse potential and accepted medical use
D. High abuse potential and accepted medical use
Correct Answer: C
Rationale: Schedule IV substances have a lower potential for abuse relative to Schedule
III. Examples include benzodiazepines, zolpidem, and tramadol .
